

Appendix 7

Sensitivity analysis on discounting and age-weighting, in Afr-E and Sear-D^a

Afr-E

Interventions	Coverage level	Incremental CER (age weighted, discounted) ^b	Incremental CER (not age weighted, discounted)	Incremental CER (not age weighted, undiscounted)
Breast Cancer				
BRE-6: Optimal program (treatment of Stages I-IV breast cancer, plus biannual mammographic screening)	50%	2,248	2,011	529
BRE-12: Optimal program (treatment of Stages I-IV breast cancer, plus biannual mammographic screening)	80%	2,253	2,022	532
BRE-18: Optimal program (treatment of Stages I-IV breast cancer, plus biannual mammographic screening)	95%	2,323	2,411	634
Cervical Cancer				
CVC-129: PAP at age 40 with lesion removal and cancer treatment	50%	307	Dominated	Dominated
CVC-4: Treatment of invasive cancer consisting of Surgery &/or Chemotherapy &/or Radiotherapy	95%	702	602	Dominated
CVC-51: PAP at age 40 +Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	756	Dominated	Dominated
CVC-35: VIA at age 40 +Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	972	Dominated	438
CVC-49: VIA (35,40,45)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	1,675	3,422	714
CVC-37: PAP(5,20,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	3,906	3,663	1,856
CVC-34: PAP(3,20,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	12,425	Dominated	Dominated
CVC-43: PAP (5,20,30) & PAP/HPV(5,30,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	13,705	10,350	5,718
CVC-33: PAP(1,20,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	27,139	33,256	13,270
CVC-39: PAP (1,20,30) & PAP/HPV(1,30,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	100,075	91,187	50,966
CVC-7: VIA at age 40 with lesion removal and cancer treatment	95%	Dominated	682	Dominated
CVC-21: VIA (35,40,45) with lesion removal and cancer treatment	95%	Dominated	702	Dominated
CVC-22: PAP at age 40 with lesion removal	95%	Dominated	273	157
CVC-26:Waning HPV at age 12 costing \$0.60 per vaccine dose	95%	Dominated	Dominated	269
CVC-32: VIA at age 40 +Waning HPV at age 12 costing \$0.60 per vaccine dose	95%	Dominated	Dominated	424
CVC-50: PAP at age 40 +Waning HPV at age 12 costing \$0.60 per vaccine dose	95%	Dominated	Dominated	298
Colorectal Cancer				
CRC-35: Treatment consisting of Surgery &/or Chemotherapy &/or Radiotherapy	80%	336	274	54
CRC-10: Treatment consisting of Surgery &/or Chemotherapy &/or Radiotherapy	95%	337	271	53
CRC-18: Colonoscopy at age 50 & surgical removal of polyps + treatment	95%	3,630	2,751	490
CRC-14: Colonoscopy screening every 10 years & surgical removal of polyps + treatment	95%	9,598	4,698	756
CRC-15: Sigmoidoscopy screening every 5 years and FOB annually & surgical removal of polyps + treatment	95%	15,548	10,030	1,969

CRC-17: Sigmoidoscopy at age 50 & surgical removal of polyps + treatment	95%	Dominated	2,724	Dominated
--	-----	-----------	-------	-----------

Sear-D

Interventions	Coverage level	Incremental CER (age weighted, discounted) ^b	Incremental CER (not age weighted, discounted)	Incremental CER (not age weighted, undiscounted)
Breast Cancer				
BRE-06: Optimal program (treatment of Stages I-IV breast cancer, plus biannual mammographic screening)	50%	4,338	3,915	Dominated
BRE-12: Optimal program (treatment of Stages I-IV breast cancer, plus biannual mammographic screening)	80%	4,362	3,938	Dominated
BRE-18: Optimal program (treatment of Stages I-IV breast cancer, plus biannual mammographic screening)	95%	4,402	4,148	1,281
BRE-13: treatment of Stage I	95%	Dominated	Dominated	798
Cervical Cancer				
CVC-129: PAP at age 40 with lesion removal and cancer treatment .	50%	142	190	152
CVC-4: Treatment of invasive cancer consisting of Surgery &/or Chemotherapy &/or Radiotherapy	95%	477	334	304
CVC-23: PAP at age 40 with lesion removal and cancer treatment	95%	757	861	Dominated
CVC-7: VIA at age 40 with lesion removal and cancer treatment	95%	1,240	962	Dominated
CVC-21: VIA inspection at ages 35,40,45 with lesion removal and cancer treatment	95%	1,719	1,198	Dominated
CVC-17: PAP smear at ages 35,40,45 with lesion removal and cancer treatment	95%	2,886	Dominated	Dominated
CVC-34: PAP(3,20,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	16,051	8,272	4,722
CVC-41: PAP (3,20,30) & PAP/HPV(3,30,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	36,764	38,425	Dominated
CVC-39: PAP (1,20,30) & PAP/HPV(1,30,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	81,629	94,733	51,181
CVC-34: PAP (3,20,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	Dominated	28,547	10,858
CVC-37: PAP(5,20,65)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	Dominated	8,114	1,173
CVC-27: Waning HPV at age 12 costing \$0.60 per vaccine dose	95%	Dominated	Dominated	145
CVC-35: VIA at age 40+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	Dominated	Dominated	816
CVC-49: VIA (35,40,45)+Waning HPV at age 12 costing \$0.60 per vaccine dose + treatment	95%	Dominated	Dominated	937
CVC-50: PAP at age 40+Waning HPV at age 12 costing \$0.60 per vaccine dose	95%	Dominated	Dominated	473
Colorectal Cancer				
CRC-10: Treatment consisting of Surgery &/or Chemotherapy &/or Radiotherapy	95%	362	278	65
CRC-17: Sigmoidoscopy at age 50 & surgical removal of polyps + treatment	95%	8,291	6,092	1,257
CRC-18: Colonoscopy at age 50 & surgical removal of polyps + treatment	95%	9,318	6,874	1,340
CRC-14: Colonoscopy screening every 10 years & surgical removal of polyps + treatment	95%	28,017	12,198	1,975
CRC-15: Sigmoidoscopy Screening every 5 years and FOB annually & surgical removal of polyps and treatment	95%	42,940	29,741	7,528

^a Table only shows incremental CERs, and lists interventions that are dominant in any of the three analysis.

^b Baseline, corresponds to results in Tables 2 and 3.

